|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TSTA3 |
Gene summary for TSTA3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TSTA3 | Gene ID | 7264 |
| Gene name | GDP-L-fucose synthase | |
| Gene Alias | FX | |
| Cytomap | 8q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0001667 | UniProtAcc | Q13630 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7264 | TSTA3 | GSM4909281 | Human | Breast | IDC | 1.98e-02 | 2.54e-01 | 0.21 |
| 7264 | TSTA3 | GSM4909285 | Human | Breast | IDC | 2.25e-25 | 6.35e-01 | 0.21 |
| 7264 | TSTA3 | GSM4909294 | Human | Breast | IDC | 4.35e-12 | 5.92e-01 | 0.2022 |
| 7264 | TSTA3 | GSM4909296 | Human | Breast | IDC | 6.64e-15 | 4.82e-01 | 0.1524 |
| 7264 | TSTA3 | GSM4909297 | Human | Breast | IDC | 8.02e-04 | 3.97e-02 | 0.1517 |
| 7264 | TSTA3 | GSM4909304 | Human | Breast | IDC | 2.68e-21 | 6.48e-01 | 0.1636 |
| 7264 | TSTA3 | GSM4909308 | Human | Breast | IDC | 5.68e-06 | 3.27e-01 | 0.158 |
| 7264 | TSTA3 | GSM4909311 | Human | Breast | IDC | 2.92e-20 | 2.76e-01 | 0.1534 |
| 7264 | TSTA3 | GSM4909312 | Human | Breast | IDC | 1.22e-21 | 6.54e-01 | 0.1552 |
| 7264 | TSTA3 | GSM4909317 | Human | Breast | IDC | 2.24e-22 | 6.36e-01 | 0.1355 |
| 7264 | TSTA3 | GSM4909319 | Human | Breast | IDC | 9.28e-26 | 6.37e-02 | 0.1563 |
| 7264 | TSTA3 | GSM4909320 | Human | Breast | IDC | 3.72e-02 | 1.57e-02 | 0.1575 |
| 7264 | TSTA3 | GSM4909321 | Human | Breast | IDC | 1.50e-08 | 2.36e-01 | 0.1559 |
| 7264 | TSTA3 | brca1 | Human | Breast | Precancer | 1.54e-09 | 4.46e-01 | -0.0338 |
| 7264 | TSTA3 | NCCBC11 | Human | Breast | DCIS | 3.07e-02 | 3.53e-01 | 0.1232 |
| 7264 | TSTA3 | NCCBC14 | Human | Breast | DCIS | 4.95e-08 | 4.06e-01 | 0.2021 |
| 7264 | TSTA3 | NCCBC2 | Human | Breast | DCIS | 4.55e-02 | 3.46e-02 | 0.1554 |
| 7264 | TSTA3 | NCCBC5 | Human | Breast | DCIS | 1.13e-08 | 1.67e-01 | 0.2046 |
| 7264 | TSTA3 | NCCBC6 | Human | Breast | DCIS | 2.05e-04 | 4.66e-01 | 0.2095 |
| 7264 | TSTA3 | P1 | Human | Breast | IDC | 1.29e-03 | -7.06e-02 | 0.1527 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa00051 | Colorectum | AD | Fructose and mannose metabolism | 17/2092 | 34/8465 | 1.25e-03 | 8.02e-03 | 5.12e-03 | 17 |
| hsa000511 | Colorectum | AD | Fructose and mannose metabolism | 17/2092 | 34/8465 | 1.25e-03 | 8.02e-03 | 5.12e-03 | 17 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TSTA3 | SNV | Missense_Mutation | novel | c.451N>C | p.Asp151His | p.D151H | Q13630 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| TSTA3 | SNV | Missense_Mutation | novel | c.742N>A | p.Asp248Asn | p.D248N | Q13630 | protein_coding | tolerated(0.07) | benign(0.007) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
| TSTA3 | SNV | Missense_Mutation | novel | c.215T>C | p.Met72Thr | p.M72T | Q13630 | protein_coding | tolerated(0.11) | possibly_damaging(0.449) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| TSTA3 | SNV | Missense_Mutation | c.431N>G | p.Ser144Trp | p.S144W | Q13630 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0R8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TSTA3 | SNV | Missense_Mutation | novel | c.166N>A | p.Ala56Thr | p.A56T | Q13630 | protein_coding | tolerated(0.1) | benign(0.15) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| TSTA3 | SNV | Missense_Mutation | novel | c.843G>T | p.Lys281Asn | p.K281N | Q13630 | protein_coding | deleterious(0.01) | probably_damaging(0.964) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TSTA3 | SNV | Missense_Mutation | c.25N>T | p.Arg9Trp | p.R9W | Q13630 | protein_coding | deleterious(0.01) | possibly_damaging(0.676) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TSTA3 | SNV | Missense_Mutation | c.239T>G | p.Ile80Ser | p.I80S | Q13630 | protein_coding | deleterious(0.03) | benign(0.044) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TSTA3 | SNV | Missense_Mutation | rs772066745 | c.628N>G | p.Thr210Ala | p.T210A | Q13630 | protein_coding | deleterious(0) | possibly_damaging(0.803) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| TSTA3 | SNV | Missense_Mutation | novel | c.316G>A | p.Ala106Thr | p.A106T | Q13630 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |